Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Alzheimers Dement. 2020 Sep 11;16(10):1345–1357. doi: 10.1002/alz.12144

Figure 5.

Figure 5.

1.5-month old 5XFAD mice treated with 51657 for 4 weeks have reduced soluble Aβ. A. Soluble Aβ42 in the combined cortex and hippocampus/subiculum of the 5XFAD study mice. Data were normalized to the vehicle mean for each sex, with n=4 vehicle- and 51657-treated male and female 5XFAD mice. Statistical comparison was by unpaired 2-tailed t-test (t=3.17, df=14). Error bars represent SEM. B. Soluble Aβ42 in the cortex (Ctx) and hippocampus/subiculum (Hip) of the 5XFAD study mice graphed by sex, with normalization to the vehicle mean from the female hippocampus/subiculum group. Error bars represent SEM, with n=4 vehicle- and 51657-treated male and female 5XFAD mice. C. Insoluble Aβ42 in the cortex and hippocampus/subiculum of the 5XFAD study mice graphed by sex, with normalization to the vehicle mean from the female hippocampus/subiculum group. Error bars represent SEM, with n=4 vehicle- and 51657-treated male and female 5XFAD mice.